Last reviewed · How we verify
FMX-103 3%
At a glance
| Generic name | FMX-103 3% |
|---|---|
| Also known as | Minocycline foam 3% |
| Sponsor | Vyne Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FMX-103 3% CI brief — competitive landscape report
- FMX-103 3% updates RSS · CI watch RSS
- Vyne Therapeutics Inc. portfolio CI